CD274 and neoplasm: In conclusion, although the study did not meet its primary endpoint, bintrafusp alfa showed clinical activity in some patients with heavily pretreated NSCLC who had primary refractory disease or who developed acquired resistance to prior treatment with anti-PD-(L)1 therapy, regardless of their prior treatment type or tumor PD-L1 expression levels.